Deutsche Bank AG Grows Stake in Qiagen N.V. $QGEN

Deutsche Bank AG increased its holdings in shares of Qiagen N.V. (NYSE:QGEN) by 9.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,907,801 shares of the company’s stock after purchasing an additional 697,342 shares during the quarter. Deutsche Bank AG’s holdings in Qiagen were worth $355,614,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Danske Bank A S purchased a new stake in shares of Qiagen during the third quarter worth about $36,000. Smartleaf Asset Management LLC lifted its stake in Qiagen by 1,383.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after purchasing an additional 830 shares in the last quarter. Manchester Capital Management LLC purchased a new stake in Qiagen in the 4th quarter worth $42,000. Global Retirement Partners LLC lifted its stake in Qiagen by 279.9% in the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after purchasing an additional 851 shares in the last quarter. Finally, Allworth Financial LP lifted its stake in Qiagen by 23.2% in the 3rd quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock worth $61,000 after purchasing an additional 256 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on QGEN. Stifel Nicolaus set a $36.00 price target on shares of Qiagen and gave the stock a “hold” rating in a research note on Monday, May 18th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $43.00 price target on shares of Qiagen in a research note on Thursday, April 30th. Zacks Research upgraded shares of Qiagen from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 29th. Robert W. Baird set a $43.00 price target on shares of Qiagen and gave the stock an “outperform” rating in a research note on Wednesday, April 29th. Finally, Citigroup reiterated a “hold” rating on shares of Qiagen in a research note on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Qiagen currently has a consensus rating of “Hold” and a consensus target price of $44.98.

Qiagen Price Performance

Shares of Qiagen stock opened at $37.03 on Thursday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.57 and a current ratio of 3.21. The stock has a 50 day moving average price of $37.19 and a 200-day moving average price of $44.17. The stock has a market cap of $7.63 billion, a price-to-earnings ratio of 19.34, a price-to-earnings-growth ratio of 3.76 and a beta of 0.66. Qiagen N.V. has a one year low of $32.53 and a one year high of $57.81.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.54 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.54. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. The business had revenue of $492.32 million for the quarter, compared to analysts’ expectations of $496.15 million. During the same quarter in the previous year, the business posted $0.56 earnings per share. Equities analysts expect that Qiagen N.V. will post 2.43 EPS for the current year.

Qiagen Increases Dividend

The company also recently declared an annual dividend, which will be paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th will be issued a dividend of $0.35 per share. This represents a yield of 104.0%. The ex-dividend date is Tuesday, July 7th. This is a positive change from Qiagen’s previous annual dividend of $0.26. Qiagen’s payout ratio is currently 13.61%.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.